percutaneous coronary intervention - antithrombotics - all type of patients clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>percutaneous coronary intervention</strong> - antithrombotics </a> - all type of patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> JUMBO-TIMI 26, 2005 </a> <br> </td> <td> Prasugrel 3 doses<br>  <i>versus</i> <br> clopidogrel 300mg loading dose followed by 75 mg daily) </td> <td> patients undergoing elective or urgent percutaneous coronary intervention </td> <td> follow-up 30 days<br> n=650/254<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> ISAR-REACT 3, 2008 </a> <br> NCT00262054 </td> <td> UFH bolus of 140 U/kg<br>  <i>versus</i> <br> bivalirudin (bolus of 0.75 mg/kg, followed by infusion of 1.75 mg/kg/hr) </td> <td> troponin-negative patients undergoing PCI </td> <td> follow-up 30 days (mean)<br> n=2289/2281<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> STEEPLE, 2006 </a> <br> NCT00077844 </td> <td> enoxaparin (0.5 or 0.75 mg per kilogram of body weight)<br>  <i>versus</i> <br> unfractionated heparin (adjusted for activated clotting time) </td> <td> elective percutaneous coronary intervention. </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> TACT, 1990 </a> <br> </td> <td> ticlopidine 500, aspirin 650 + D225<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 6m<br> n=177/173<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Schwartz (Toronto), 1988 </a> <br> </td> <td> aspirin 990 + D225 (H)<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up 6m<br> n=187/189<br> Parallel groups<br> double blind <br> Canada </td> </tr> <tr> <td> <a href="index.html"> White (aspirin+dipiridamol), 1991 </a> <br> </td> <td> ticlopidine 500, aspirin 650 + D225<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 6m<br> n=245/254<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Finci, 1989 </a> <br> </td> <td> ST<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 6m<br> n=54/53<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Taylor (Perth), 1991 </a> <br> </td> <td> aspirin, 100 mg/day after 2 weeks<br>  <i>versus</i> <br> placebo </td> <td> patients aged less than 70 years without acute infarction undergoing PTCA </td> <td> follow-up 6m<br> n=124/128<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> Nye (Dunedin), 1990 </a> <br> </td> <td> aspirin 300 + D225<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up 12m<br> n=35/37<br> Parallel groups<br> NA <br> </td> </tr> <tr> <td> <a href="index.html"> Mayo-PTCA, 1989 </a> <br> </td> <td> aspirin 975 + D225<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 48h<br> n=102/105<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> Oriol, 1995 </a> <br> </td> <td> TF 900<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 6m<br> n=171/171<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> M-HEART II (aspirin), 1995 </a> <br> </td> <td> aspirin 325 mg daily<br>  <i>versus</i> <br> placebo </td> <td> patients undergoing PTCA </td> <td> follow-up 6m<br> n=497/510<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> REPLACE-2, 2003 </a> <br> </td> <td> bivalirudin, with glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition on a provisional basis for complications during PCI<br>  <i>versus</i> <br> heparin plus planned Gp IIb/IIIa blockade </td> <td> patients undergoing urgent or elective PCI </td> <td> follow-up 30 days<br> n=2994/3008<br> Parallel groups<br> double blind <br> 9 countries </td> </tr> <tr> <td> <a href="index.html"> White (ticlopidine), 1991 </a> <br> </td> <td> ticlopidine 500, aspirin 650 + D225<br>  <i>versus</i> <br> placebo </td> <td> </td> <td> follow-up 6m<br> n=-9/254<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> M-HEART II (sulotroban), 1995 </a> <br> </td> <td> <br>  <i>versus</i> <br> placebo </td> <td> patients undergoing PTCA </td> <td> follow-up 6 months<br> n=752/0<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> HORIZONS-AMI (Stone), 2008 </a> <br> NCT00433966 </td> <td> Bivalirudin<br>  <i>versus</i> <br> Heparin plus GP IIb/IIIa inhibitor </td> <td> patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI </td> <td> follow-up 30 days<br> n=1800/1802<br> Parallel groups<br> open <br> 11 countries </td> </tr> <tr> <td> <a href="index.html"> ACUITY (Stone) (bivalirudin alone), 2006 </a> <br> NCT00093158 </td> <td> bivalirudin alone<br>  <i>versus</i> <br> unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor </td> <td> patients with acute coronary syndromes </td> <td> follow-up 30 days<br> n=9216/4603<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> REPLACE-1, 2004 </a> <br> </td> <td> bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/h infusion during the procedure<br>  <i>versus</i> <br> heparin (70 U/kg initial bolus) adjusted to ACT of 200 to 300s </td> <td> patients undergoing elective or urgent revascularization </td> <td> follow-up hospital stay (48h min)<br> n=532/524<br> Parallel groups<br> <br> US </td> </tr> <tr> <td> <a href="index.html"> Kleiman, 2002 </a> <br> </td> <td> bivalirudin + eptifibatide<br>  <i>versus</i> <br> heparin + eptifibatide </td> <td> patients who underwent elective percutaneous coronary intervention </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> BAT (Bittl), 1995 </a> <br> </td> <td> bivalirudin immediately before angioplasty.<br>  <i>versus</i> <br> heparin immediately before angioplasty </td> <td> patients undergoing urgent angioplasty for unstable or postinfarction angina </td> <td> follow-up hospital stay<br> n=2059/2039<br> Parallel groups<br> double blind <br> US </td> </tr> <tr> <td> <a href="index.html"> REDUCE, 1996 </a> <br> </td> <td> Reviparin 7,000 IU anti-Xa<br>  <i>versus</i> <br> UFH 10,000 IU bolus </td> <td> PTCA with stable/unstable angina </td> <td> follow-up 3 days<br> n=306/306<br> Parallel groups<br> double blind <br> Europe and Canada </td> </tr> <tr> <td> <a href="index.html"> Rabah, 1999 </a> <br> </td> <td> Enoxaparin 1 mg/kg bolus<br>  <i>versus</i> <br> UFH 10,000 IU bolus, then titrated to ACT > 300 </td> <td> PCI for stable angina </td> <td> follow-up <br> n=30/30<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> CRUISE, 2003 </a> <br> </td> <td> Enoxaparin 0.75 mg/kg bolus<br>  <i>versus</i> <br> UFH 60 IU/kg bolus, then titrated to ACT > 200 </td> <td> Urgent or elective PCI </td> <td> follow-up 2,7 +30 days<br> n=129/132<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Galeote, 2001 </a> <br> </td> <td> Enoxaparin 0.75 mg/kg bolus<br>  <i>versus</i> <br> UFH 70 U/kg bolus, then titrated to ACT > 200 </td> <td> PTCA patients with stable/unstable angina or AMI </td> <td> follow-up <br> n=50/49<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Dudek, 2000 </a> <br> </td> <td> Enoxaparin 1 mg/kg bolus<br>  <i>versus</i> <br> UFH titrated to ACT > 300 </td> <td> PCI </td> <td> follow-up 3� days<br> n=200/200<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Dudek b (enox alone), 2000 </a> <br> </td> <td> Enoxaparin 1 mg/kg bolus<br>  <i>versus</i> <br> UFH titrated to ACT > 300 </td> <td> PTCA complex lesionsCI </td> <td> follow-up <br> n=-9/50<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Drozd, 2001 </a> <br> </td> <td> Enoxaparin 1 mg/kg bolus<br>  <i>versus</i> <br> UFH 100 IU/kg bolus </td> <td> PCI for stable angina </td> <td> follow-up 24hrs, 30 days<br> n=50/50<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Natarajan (without antiGp2b3a), 2003 </a> <br> </td> <td> Dalteparin 100 IU/kg bolus<br>  <i>versus</i> <br> UFH 100 IU/kg bolus </td> <td> Elective or urgent PCI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Dubek b (+abciximal), 2001 </a> <br> </td> <td> Enoxaparin 0.75 mg/kg bolus + abciximab<br>  <i>versus</i> <br> UFH titrated to ACT > 300 </td> <td> </td> <td> follow-up <br> n=-9/50<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Natarajan (+ antiGp2b3a), 2003 </a> <br> </td> <td> Dalteparin 70 IU/kg bolus + GP IIb/IIIa inhibitorse/p<br>  <i>versus</i> <br> UFH 70 IU/kg bolus +GPIIb/IIIa inhibitors </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> RAPPORT, 1998 </a> <br> </td> <td> loading dose 250�g/kg infusion 0.125�g/kg/min for 12h<br>  <i>versus</i> <br> </td> <td> Primary PTCA < </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> ADMIRAL, 2001 </a> <br> </td> <td> loading dose 250�g/kg infusion 0.125�g/kg/min for 12h<br>  <i>versus</i> <br> </td> <td> Primary PCI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> CADILLAC, 2002 </a> <br> </td> <td> loading dose 250�g/kg infusion 0.125�g/kg/min for 12h<br>  <i>versus</i> <br> </td> <td> Primary PCI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> EPIC (with infusion), 1994 </a> <br> </td> <td> loading dose 250�g/kg infusion 10�g/min for 12h<br>  <i>versus</i> <br> </td> <td> High risk for abrupt closurebitm </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> EPILOG, 1997 </a> <br> </td> <td> loading dose 250�g/kg infusion 0.125�g/kg/min (max 10�g) for 12h<br>  <i>versus</i> <br> </td> <td> Elective or urgent PCIe </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> EPISTENT, 1998 </a> <br> </td> <td> loading dose 250�g/kg infusion 0.125�g/kg/min for 12h<br>  <i>versus</i> <br> </td> <td> Elective or urgent PCI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> CAPTURE, 1997 </a> <br> </td> <td> loading dose 250�g/kg infusion 10�g/min for 18-24h<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> ERASER, 1999 </a> <br> </td> <td> loading dose �g/kg infusion �g/min for h<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Petronio, 2002 </a> <br> </td> <td> loading dose �g/kg infusion �g/min for h<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Simoons, 1994 </a> <br> </td> <td> loading dose �g/kg infusion �g/min for h<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Kini, 2001 </a> <br> </td> <td> loading dose �g/kg infusion �g/min for h<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Tamburino, 2002 </a> <br> </td> <td> loading dose �g/kg infusion �g/min for h<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> ISAR-2, 2000 </a> <br> </td> <td> loading dose 250�g/kg infusion 10�g/min for 12h<br>  <i>versus</i> <br> </td> <td> PCI <48 h after MI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> IMPACT (4h), 1995 </a> <br> </td> <td> loading dose 90�g/kg infusion 1.0�g/kg/min for 4h<br>  <i>versus</i> <br> </td> <td> Elective PCI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> IMPACT-II (0.5�g), 1997 </a> <br> </td> <td> loading dose 135�g/kg infusion 0.5�g/kg/min for 20-24h<br>  <i>versus</i> <br> </td> <td> Any PCI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> ESPRIT, 2000 </a> <br> </td> <td> loading dose 180�g/kg x2 infusion 2�g/min for 18-24h<br>  <i>versus</i> <br> </td> <td> Nonurgent PCI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Harrington, 1995 </a> <br> </td> <td> loading dose �g/kg infusion �g/min for h<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> RESTORE, 1997 </a> <br> </td> <td> loading dose 10�g/kg infusion 0.15�g/kg/min for 36h<br>  <i>versus</i> <br> </td> <td> PCI <72 h after USA or MI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Kereiakis, 1996 </a> <br> </td> <td> loading dose �g/kg infusion �g/min for h<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> EPIC (without infusion), 1991 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> IMPACT (12h), 1993 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> IMPACT-II (0.75�g), 1994 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> TRA-PCI, 2009 </a> <br> NCT00132912 </td> <td> SCH 530348 3 doses: 10mg, 20mg and 40mg<br>  <i>versus</i> <br> placebo </td> <td> patients aged 45 years or older and undergoing non-urgent PCI or coronary angiography with planned PCI </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="index.html"> CHAMPION-PLATFORM, 2009 </a> <br> NCT00385138 </td> <td> cangrelor up front (cangrelor during PCI followed by 600 mg of clopidogrel)<br>  <i>versus</i> <br> delayed clopidogrel (placebo during PCI followed by 600 mg of clopidogrel) </td> <td> patients with acute coronary syndrome undergoing percutaneous coronary intervention </td> <td> follow-up 48 h<br> n=2693/2669<br> Parallel groups<br> double blind <br> 18 countries </td> </tr> <tr> <td> <a href="index.html"> CHAMPION-PCI, 2009 </a> <br> NCT00305162 </td> <td> cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel)<br>  <i>versus</i> <br> clopidogrel up front (clopidogrel followed by placebo) </td> <td> high risk patients requiring PCI </td> <td> follow-up 48 h<br> n=4367/4355<br> Parallel groups<br> double blind <br> 14 countries </td> </tr> <tr> <td> <a href="index.html"> NAPLES (Tavano), 2009 </a> <br> </td> <td> bivalirudin monotherapy<br>  <i>versus</i> <br> unfractionated heparin plus tirofiban </td> <td> patients with diabetes mellitus undergoing elective percutaneous coronary intervention </td> <td> follow-up 30 days<br> n=167/168<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="index.html"> ATOLL, 2010 </a> <br> </td> <td> IV enoxaparin<br>  <i>versus</i> <br> UFH </td> <td> patients undergoing PCI for acute STEMI </td> <td> follow-up 30 days<br> n=450/460<br> Parallel groups<br> open <br> Austria, France, Germany, and US </td> </tr> <tr> <td> <a href="index.html"> STREAM, </a> <br> NCT00882635 </td> <td> Enoxaparin<br>  <i>versus</i> <br> Unfractionated Heparin </td> <td> St Elevation Myocardial Infarction patients undergoing primary percutaneous coronary intervention </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> TRIGGER-PCI, </a> <br> NCT00910299 </td> <td> prasugrel one time 60-mg oral loading dose and 10-mg once daily oral maintenance dose up to 6 months<br>  <i>versus</i> <br> clopidogrel 75-mg oral daily maintenance dose up to 6 months </td> <td> patients With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent </td> <td> follow-up 6 months<br> n=-9/-9<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> BRAVE-4, </a> <br> NCT00976092 </td> <td> Prasugrel + Bivalirudin<br>  <i>versus</i> <br> Clopidogrel + Heparin </td> <td> STEMI patients undergoing PPCI </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> </table> <h2>References</h2> <p> <b>JUMBO-TIMI 26, 2005 : </b> Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald ERandomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. <i>Circulation 2005 Jun 28;111:3366-73</i> [PMID 15967851] </p> <p> <b>ISAR-REACT 3, 2008 : </b> Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, B�ttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Sch�mig ABivalirudin versus Unfractionated Heparin during Percutaneous Coronary Intervention. <i>N Engl J Med 2008 Aug 14;359:688-696</i> [PMID 18703471] </p> <p> <b>STEEPLE, 2006 : </b> Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SREnoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. <i>N Engl J Med 2006;355:1006-17</i> [PMID 16957147] </p> <p> <b>TACT, 1990 : </b> Bertrand ME, Allain H, LaBlanche JM, on behalf of Investigators of the TACT StudyResults of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA): the TACT study <i>Circulation 1990;82(suppl III):190 (Abstract 0754)</i> [PMID ] </p> <p> <b>Schwartz (Toronto), 1988 : </b> Schwartz L, Bourassa MG, Lesp�rance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PRAspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. <i>N Engl J Med 1988;318:1714-9</i> [PMID 2967433] </p> <p> <b>White (aspirin+dipiridamol), 1991 : </b> White CW, Chaitman B, Knudtson ML, Chisholm RJ, and the Ticlopidine Study Group.Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis: results from the ticlopidine trial <i>Coronary Artery Dis 1991;2:757-67</i> [PMID ] </p> <p> <b>Finci, 1989 : </b> Finci L, H�fling B, Ludwig B, Bulitta M, Steffino G, Etti H, et al.Sulotroban during and after coronary angioplasty. A double-blind placebo controlled study <i>Zeitschrift f�r Kardiologie 1989;78(suppl 3):50-4</i> [PMID ] </p> <p> <b>Taylor (Perth), 1991 : </b> Taylor RR, Gibbons FA, Cope GD, Cumpston GN, Mews GC, Luke PEffects of low-dose aspirin on restenosis after coronary angioplasty. <i>Am J Cardiol 1991;68:874-8</i> [PMID 1927946] </p> <p> <b>Nye (Dunedin), 1990 : </b> Nye ER, Ablett MB, Robertson MC, Ilsley CD, Sutherland WHEffect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. <i>Aust N Z J Med 1990;20:549-52</i> [PMID 2222347] </p> <p> <b>Mayo-PTCA, 1989 : </b> Chesebro JH, Webster MW, Reeder GS, Mock MB, Grill DE, Bailey KR, et al.Coronary angioplasty: antiplatelet therapy reduces acute complications but not restenosis <i>Circulation 1989;80 (suppl II):II-64 (Abstract 0257)</i> [PMID ] </p> <p> <b>Oriol, 1995 : </b> Oriol A.Multicentre, double-blind study of triflusal in comparison to placebo in patients after percutaneous transluminal coronary angioplasty/x <i>Barcelona, Spain: J. Uriach & C�a., S.A., 1995:(Internal report TRI1-90/IV- 04)</i> [PMID ] </p> <p> <b>M-HEART II (aspirin), 1995 : </b> Savage MP, Goldberg S, Bove AA, Deutsch E, Vetrovec G, Macdonald RG, Bass T, Margolis JR, Whitworth HB, Taussig AEffect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) <i>Circulation 1995;92:3194-200</i> [PMID 7586303] </p> <p> <b>CURE PCI import�, 2001 : </b> Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KAEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. <i>Lancet 2001;358:527-33</i> [PMID 11520521] </p> <p> <b>REPLACE-2, 2003 : </b> Gibson CM, Ten Y, Murphy SA, Ciaglo LN, Southard MC, Lincoff AM, Waksman R, Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis). <i>Am J Cardiol 2007;99:1687-90.</i> [PMID 17560876] 10.1016/j.amjcard.2007.01.053 </p> <p> <b>REPLACE-2, 2003 : </b> Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ, Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. <i>J Am Coll Cardiol 2004;44:1792-800.</i> [PMID 15519009] 10.1016/j.jacc.2004.05.085 </p> <p> <b>REPLACE-2, 2003 : </b> Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, , Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. <i>JAMA 2004;292:696-703.</i> [PMID 15304466] 10.1001/jama.292.6.696 </p> <p> <b>REPLACE-2, 2003 : </b> Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJBivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. <i>JAMA 2003 Feb 19;289:853-63</i> [PMID 12588269] </p> <p> <b>M-HEART II (sulotroban), 1995 : </b> Savage MP, Goldberg S, Bove AA, Deutsch E, Vetrovec G, Macdonald RG, Bass T, Margolis JR, Whitworth HB, Taussig AEffect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) <i>Circulation 1995 Dec 1;92:3194-200</i> [PMID 7586303] </p> <p> <b>HORIZONS-AMI (Stone), 2008 : </b> Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW, The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. <i>Am Heart J 2008;156:44-56.</i> [PMID 18585496] 10.1016/j.ahj.2008.02.008 </p> <p> <b>HORIZONS-AMI (Stone), 2008 : </b> Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran RBivalirudin during primary PCI in acute myocardial infarction. <i>N Engl J Med 2008 May 22;358:2218-30</i> [PMID 18499566] </p> <p> <b>HORIZONS-AMI (Stone) doublons � effacer, 2008 : </b> Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, , Bivalirudin during primary PCI in acute myocardial infarction. <i>N Engl J Med 2008;358:2218-30.</i> [PMID 18499566] 10.1056/NEJMoa0708191 </p> <p> <b>ACUITY (sub groups, bivalirudin alone), 2007 : </b> Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ, , Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. <i>JAMA 2007;298:2497-506.</i> [PMID 18056903] 10.1001/jama.298.21.2497 </p> <p> <b>ACUITY (sub groups, bivalirudin alone), 2007 : </b> Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, , Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. <i>Lancet 2007;369:907-19.</i> [PMID 17368152] 10.1016/S0140-6736(07)60450-4 </p> <p> <b>ACUITY (sub groups, bivalirudin alone), 2007 : </b> Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD, Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. <i>Am Heart J 2004;148:764-75.</i> [PMID 15523305] 10.1016/j.ahj.2004.04.036 </p> <p> <b>ACUITY (Stone) (bivalirudin alone), 2006 : </b> Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, , Bivalirudin for patients with acute coronary syndromes. <i>N Engl J Med 2006;355:2203-16.</i> [PMID 17124018] 10.1056/NEJMoa062437 </p> <p> <b>REPLACE-1, 2004 : </b> Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J, Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ, , Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). <i>Am J Cardiol 2004;93:1092-6.</i> [PMID 15110198] 10.1016/j.amjcard.2004.01.033 </p> <p> <b>CACHET (without abciximab), 2002 : </b> Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh K, Wolski KE, Topol EJ, Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). <i>Am Heart J 2002;143:847-53.</i> [PMID 12040347] </p> <p> <b>Kleiman, 2002 : </b> Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T, Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. <i>Am Heart J 2002;143:585-93.</i> [PMID 11923794] </p> <p> <b>BAT (Bittl), 1995 : </b> Bittl JA, Feit F, A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators. <i>Am J Cardiol 1998;82:43P-49P.</i> [PMID 9809891] </p> <p> <b>BAT (Bittl), 1995 : </b> Shah PB, Ahmed WH, Ganz P, Bittl JA, Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. <i>J Am Coll Cardiol 1997;30:1264-9.</i> [PMID 9350925] </p> <p> <b>BAT (Bittl), 1995 : </b> Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. <i>N Engl J Med 1995;333:764-9.</i> [PMID 7643883] </p> <p> <b>BAT (Bittl), 1995 : </b> Bittl JA, Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators. <i>Am Heart J 1995;130:658-65.</i> [PMID 7668214] </p> <p> <b>BAT (Bittl), 1995 : </b> Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJBivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. <i>Am Heart J 2001;142:952-9</i> [PMID 11717596] </p> <p> <b>ISAR REACT 2, 2008 : </b> Ndrepepa G, Kastrati A, Mehilli J, Neumann FJ, ten Berg J, Bruskina O, Dotzer F, Seyfarth M, Pache J, Dirschinger J, Berger PB, Sch�mig AOne-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. <i>Eur Heart J 2008;29:455-61</i> [PMID 18158289] </p> <p> <b>REDUCE, 1996 : </b> Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan RLow molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation. <i>J Am Coll Cardiol 1996;28:1437-43</i> [PMID 8917255] </p> <p> <b>Rabah, 1999 : </b> Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CLUsefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. <i>Am J Cardiol 1999;84:1391-5</i> [PMID 10606110] </p> <p> <b>CRUISE, 2003 : </b> Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AMSafety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. <i>J Am Coll Cardiol 2003;41:20-5</i> [PMID 12570939] </p> <p> <b>Galeote, 2001 : </b> Galeote G, Hussein M, Sobrino N, Calvo L, Yunda H, Sa�nchez-Combination abciximab and enoxaparin or unfractionated heparin during percutaneous coronary intervention: a randomised study <i>Eur Heart J 2001;22(Suppl):663</i> [PMID ] </p> <p> <b>Dudek, 2000 : </b> Dudek D, Dabrowski M, Ochala A, Lesaik M, Wnek A, BryniarskiMulticenter, prospective, double-blind randomized comparison of enoxaparin versus unfractionated heparin for percutaneous coronary interventions <i>Am J Cardiol 2000;86(Suppl 8A):15i. imag</i> [PMID ] </p> <p> <b>Dudek b (enox alone), 2000 : </b> Dudek D, Bartus S, Zymek P, Legutko J, Rzeszutko L, Janion M,Abciximab and enoxaparin administration during elective high-risk PTCA in patients with more than 3 days of ticlopidine pretreatment. <i>J Am Coll Cardiol 2000;35(Suppl):91A</i> [PMID ] </p> <p> <b>Drozd, 2001 : </b> Drozd J, Opalin�ska E, Wojcik J, Madejczyk A.PagThe use of enoxaparin during percutaneous coronary angioplasty in patients with stable angina <i>Kardiol Pol 2001;55:520�524</i> [PMID ] </p> <p> <b>Natarajan (without antiGp2b3a), 2003 : </b> NatarajanMK, Turpie GA, Raco DL, Velianon JL,Mehta SR, AfzalA randomized comparison of dalteparin versus unfractioned heparin during percutaneous coronary interventions. <i>J Am Coll Cardiol 2003;41(Suppl A):68A�69A.xtPag</i> [PMID ] </p> <p> <b>RAPPORT, 1998 : </b> Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJRandomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. <i>Circulation 1998;98:734-41</i> [PMID 9727542] </p> <p> <b>ADMIRAL, 2001 : </b> Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansi�ri M, Choussat R, Pinton PPlatelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. <i>N Engl J Med 2001;344:1895-903</i> [PMID 11419426] </p> <p> <b>CADILLAC, 2002 : </b> Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJComparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. <i>N Engl J Med 2002;346:957-66</i> [PMID 11919304] </p> <p> <b>EPIC (with infusion), 1994 : </b> Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. <i>N Engl J Med 1994;330:956-61</i> [PMID 8121459] </p> <p> <b>EPIC (with infusion), 1994 : </b> Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston MRandomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. <i>Lancet 1994;343:881-6</i> [PMID 7908357] </p> <p> <b>EPIC (with infusion), 1994 : </b> Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RMLong-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. <i>JAMA 1997;278:479-84</i> [PMID 9256222] </p> <p> <b>EPILOG, 1997 : </b> Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. <i>N Engl J Med 1997;336:1689-96</i> [PMID 9182212] </p> <p> <b>EPISTENT, 1998 : </b> Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. <i>Lancet 1998;352:87-92</i> [PMID 9672272] </p> <p> <b>EPISTENT, 1998 : </b> Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJComplementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. <i>N Engl J Med 1999;341:319-27</i> [PMID 10423466] </p> <p> <b>EPISTENT, 1998 : </b> Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RMOutcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. <i>Lancet 1999;354:2019-24</i> [PMID 10636365] </p> <p> <b>CAPTURE, 1997 : </b> Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. <i>Lancet 1997;349:1429-35</i> [PMID 9164316] </p> <p> <b>ERASER, 1999 : </b> Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. <i>Circulation 1999;100:799-806</i> [PMID 10458714] </p> <p> <b>Petronio, 2002 : </b> Petronio AS, Musumeci G, Limbruno U, De Carlo M, Baglini R, Paterni G, Grazia Delle Donne M, Caravelli P, Nardi C, Mariani MAbciximab improves 6-month clinical outcome after rescue coronary angioplasty. <i>Am Heart J 2002;143:334-41</i> [PMID 11835040] </p> <p> <b>Simoons, 1994 : </b> Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TFRandomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. <i>Circulation 1994;89:596-603</i> [PMID 7508826] </p> <p> <b>Kini, 2001 : </b> Kini A, Reich D, Marmur JD, Mitre CA, Sharma SKReduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial. <i>Am Heart J 2001;142:965-9</i> [PMID 11717598] </p> <p> <b>Tamburino, 2002 : </b> Tamburino C, Russo G, Nicosia A, Galassi AR, Foti R, Scriffignano V, Kereiakes DJ, Giuffrida GProphylactic abciximab in elective coronary stenting: results of a randomized trial. <i>J Invasive Cardiol 2002;14:72-9</i> [PMID 11818641] </p> <p> <b>ISAR-2, 2000 : </b> Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleef M, Seyfarth M, Dirschinger J, Sch�mig AEffect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. <i>J Am Coll Cardiol 2000;35:915-21</i> [PMID 10732888] </p> <p> <b>IMPACT (4h), 1995 : </b> Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJMulticenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. <i>Circulation 1995;91:2151-7</i> [PMID 7697843] </p> <p> <b>IMPACT-II (0.5�g), 1997 : </b> Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. <i>Lancet 1997;349:1422-8</i> [PMID 9164315] </p> <p> <b>ESPRIT, 2000 : </b> Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. <i>Lancet 2000;356:2037-44</i> [PMID 11145489] </p> <p> <b>Harrington, 1995 : </b> Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose DImmediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. <i>Am J Cardiol 1995;76:1222-7</i> [PMID 7503000] </p> <p> <b>RESTORE, 1997 : </b> Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. <i>Circulation 1997;96:1445-53</i> [PMID 9315530] </p> <p> <b>RESTORE, 1997 : </b> Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, King SB 3rdSix-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. <i>J Am Coll Cardiol 1998;32:28-34</i> [PMID 9669245] </p> <p> <b>Kereiakis, 1996 : </b> Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FLRandomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. <i>J Am Coll Cardiol 1996;27:536-42</i> [PMID 8606262] </p> <p> <b>Topol, 1993 : </b> Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony JUse of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. <i>Circulation 1993;87:1622-9</i> [PMID 8491018] </p> <p> <b>BRIEF PCI, 2009 : </b> Fung AY, Saw J, Starovoytov A, Densem C, Jokhi P, Walsh SJ, Fox RS, Humphries KH, Aymong E, Ricci DR, Webb JG, Hamburger JN, Carere RG, Buller CEAbbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. <i>J Am Coll Cardiol 2009 Mar 10;53:837-45</i> [PMID 19264239] 10.1016/j.jacc.2008.09.060 </p> <p> <b>TRA-PCI, 2009 : </b> Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RASafety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. <i>Lancet 2009 Mar 14;373:919-28</i> [PMID 19286091] 10.1016/S0140-6736(09)60230-0 </p> <p> <b>FATA, 2009 : </b> Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, Rocchi G, Biagini E, Reggiani ML, Giacometti P, Piovaccari G, Manari A, Marzocchi ALeft ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial). <i>Am J Cardiol 2009 Mar 15;103:785-90</i> [PMID 19268732] 10.1016/j.amjcard.2008.11.029 </p> <p> <b>CHAMPION-PLATFORM, 2009 : </b> Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RAIntravenous Platelet Blockade with Cangrelor during PCI. <i>N Engl J Med 2009 Nov 15;:</i> [PMID 19915222] </p> <p> <b>CHAMPION-PCI, 2009 : </b> Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DLPlatelet inhibition with cangrelor in patients undergoing PCI. <i>N Engl J Med 2009 Dec 10;361:2318-29</i> [PMID 19915221] </p> <p> <b>NAPLES (Tavano), 2009 : </b> Tavano D, Visconti G, D'Andrea D, Focaccio A, Golia B, Librera M, Caccavale M, Ricciarelli B, Briguori CComparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention. <i>Am J Cardiol 2009;104:1222-8</i> [PMID 19840566] </p>